CRISPR Therapeutics AG
ALLOGENEIC CELL THERAPY OF ACUTE LYMPHOBLASTIC LEUKEMIA USING GENETICALLY ENGINEERED T CELLS TARGETING CD19

Abstract:

Methods for treating a B cell malignancy comprising a population of genetically engineered immune cells (e.g., T cells), which express a chimeric antigen receptor (CAR) specific to CD19 and optionally an NK cell inhibitor (e.g., daratumumab). The genetically engineered immune cells may comprise a disrupted TRAC gene, a disrupted .beta.2M gene, or both.